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This review summarises the latest evidence for the use of glutamine (GLN) in oncology taking cognisance of current systematic 
reviews and available guidelines. Various studies in adults suggest that GLN supplementation suppresses tumour growth, by 
restoring the function of natural killer cells; improves protein metabolism; and, possibly enhances the effect of cancer therapy. 
There is insufficient data on whether GLN supplementation reduces the incidence of infection, although a trend exists towards 
such a reduction. GLN-supplemented enteral nutrition was superior in improving immune function, whilst oral GLN alone 
appeared to have no effect on: mortality; infections; time to neutrophil recovery; or, relapse. GLN significantly reduces the duration 
of diarrhoea, but had no effect on its prevention. Oral GLN may reduce the duration and severity of mucositis, with fewer days 
on opioid therapy. Oral GLN, but not intravenous GLN (IV-GLN), may decrease mucositis and graft-versus-host disease in adult 
bone marrow transplant patients. Currently, the evidence for reduction of severe mucositis or infection rate in children is not 
statistically significant, but GLN does significantly reduce parenteral nutrition use, reflecting a possible improvement in lower gut 
mucositis. Nevertheless, too few studies exist to either support or refute that GLN supplementation either reduces the duration 
of, or prevents the progression to, severe mucositis. In children, there is no significant evidence that IV-GLN supplementation 
reduces infection rates, hospital length of stay (LOS), graft-versus-host disease, or mortality. Children with solid tumours on 
chemotherapy receiving oral GLN supplementation showed significant improvements in some nutritional and immunological 
parameters, as well as the severity of stomatitis and need for antibiotic therapy.
Caution is recommended when considering provision of IV-GLN to oncology patients who have hepatic or renal insufficiency 
or failure. Monitoring of hepatic and renal function is recommended. Further studies are needed specifically on the use of 
glutamine in an oncology setting. Larger, multicentre, randomised placebo-controlled studies are needed in both adult and 
paediatric oncology populations.
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Introduction
Glutamine (GLN) is a non-essential branched-chain amino acid 
that becomes conditionally essential when demand exceeds 
supply during catabolic stress or periods of rapid growth.1,2 GLN 
contributes 30–35% of the amino acid-based nitrogen in 
plasma,3,4 plays an important role in gluconeogenesis,4 and 
serves as a fuel for rapidly dividing and growing cells (e.g. 
enterocytes and lymphocytes).2,5 It contains two ammonia 
groups: glutamate and ammonia.3 GLN transports ammonia in a 
non-toxic form, from the peripheral tissue to visceral organs, 
where it is excreted in the urine.4 GLN is also used by the gut and 
kidneys for acid-base homeostatis.4
Healthy subjects have an endogenous GLN production of 50–
80  g/day.6 GLN forms 25% of the free amino acid pool in the 
extracellular fluid and 60% in the skeletal muscle,7 which is the 
main site for L-glutamine synthesis and storage.3 It is also found 
in smaller amounts in the lungs and brain.4,5 Good dietary sources 
of GLN are dairy, fish and green leafy vegetables.3
GLN depletion occurs under catabolic conditions, such as cancer, 
injury and infection.8 The skeletal muscle contributes significant 
amounts of GLN to the GLN pool during these states, causing a 
marked GLN depletion in skeletal muscle over time, due to an 
inability to meet the body’s demands.3,9 For each gram of 
nitrogen lost during stress, approximately 30 g of lean tissue is 
broken down, thereby releasing alanine and GLN.10 In a cancer 
patient, it is thought that GLN depletion, due to the side effects 
of chemotherapy and radiation, may lead to mucositis, lowered 
immunity, cachexia, increased acute-phase proteins and 
hyperlipidaemia.11,12
GLN plays an important role during the acute phase response 
(Figure 1), a catabolic state that leads to the increased production 
of counter-regulatory hormones (e.g. cortisol, glucagon) and 
cytokines (e.g. interleukin 1, interleukin 6, tumour-necrosis 
factor-α), which modulate the metabolic response. The increase 
in the synthesis of these mediators results in a decrease in 
anabolic hormones, including insulin, which leads to peripheral 
insulin resistance. Glycogen stores are usually depleted within 
the first two days of the metabolic response, resulting in lipolysis, 
proteolysis, and increased skeletal muscle breakdown for energy 
production. Immobility also contributes to further poor protein 
synthesis. The enzyme glutamine synthetase, present in skeletal 
muscle, responds to the increase in cortisol by up-regulating 
GLN release from skeletal muscle. Normally, GLN will be released 
to the glutamine pool, but, in catabolism, proteolysis leads to the 
de novo synthesis of GLN from other amino acids. When demand 
exceeds supply, the GLN pool is depleted and normal GLN-
dependent biological functions are compromised, leading to 
poor wound healing, acid-base imbalance, and compromised 
immunity.2,13
During the systemic inflammatory response syndrome (SIRS), the 
blood concentrations of water-soluble vitamins and trace 
elements (e.g. selenium, zinc and iron) are compromised, leading 
to a decreased circulatory concentration of these antioxidants, as 
well as their transport proteins (e.g. transferrin and albumin). The 
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deficit in circulatory antioxidants leads to oxidative stress when 
reactive oxygen species overcome the antioxidants’ defences, 
leading to poor wound healing, organ dysfunction, an altered 
immune response and an adverse patient outcome.1,13 GLN is 
also a precursor of glutathione, another antioxidant. Thus, GLN 
up-regulates glutathione synthesis during stress, and induces 
heat shock proteins (e.g. HSP 27, 70 and 72), assisting in 
protecting the gut and myocardium.3,14 The GLS2 gene, which 
codes for glutamine enzymes (glutaminases), is regulated by 
tumour suppressor p53. During stress, over-expression of GLS2 
reduces colony formation in tumour cells, thereby regulating 
tumour suppression.1
Therefore, supporting a patient through exogenous sources of 
GLN (either IV or orally), may assist in halting or reversing, in 
extent, the effects of GLN depletion in a catabolic patient. It is 
also possible that oral glutamine supplementation may increase 
the selectivity of anti-tumour drugs and protect against 
radiotherapy-induced oxidative stress, owing to increased 
glutathione synthesis.3 Adequate nutrition support, which 
includes GLN, will meet GLN needs and spare energy reserves, 
thereby retarding the onset of severe complications, improving 
the general metabolic state of the patient, and thus improving 
quality of life (QoL).12
Multiple studies over a twenty-year period have shown the 
benefits of using GLN when appropriately given to a specific 
patient that needs it, at the recommended approved dose for the 
specific clinical setting, and as part of nutritional therapy, thereby 
reducing mortality, infectious complications, and hospital LOS in 
critical illness.15 However, GLN supplementation remains 
controversial in the clinical setting, even though there is a 
biological rationale for its use.16
Glutamine supplementation
General
Wischmeyer15 compared the difference between ‘traditional’ IV-
GLN supplementation trials and the ‘reducing deaths due to 
oxidative stress’ (REDOXS) trial. In ‘traditional’ trials, IV-GLN 
administration was only started later in the intensive care unit 
(ICU) when patients were stable, renal and liver failure patients 
were almost universally excluded, GLN was given at lower doses 
(0.3–0.5  g/kg body weight/day) and was given only as part of 
parenteral nutrition (not combined with enteral GLN). The 
REDOXS trial ignored previous inclusion and exclusion criteria of 
‘traditional’ studies, thereby administering GLN independently 
from nutrition support to patients who were in shock or had 
multiple organ failure (MOF), at higher doses, and via multiple 
routes (enteral 30 g/d and intravenously 0.5 g/kg/d, totaling 0.6–
0.8  g/kg/d). Interestingly, many of the ‘traditional’ trials’ 
participants were surgical oncology patients, whereas the 
majority of patients in the REDOXS trial were not.15 Wischmeyer, 
who was a co-author of the REDOXS trial, was of the opinion that 
GLN supplementation was still safe to administer to appropriate 
patient groups, either intravenously at 0.35  g/kg body weight/
day or enterally at 0.5 g/kg bodyweight/day, and that the REDOXS 
trial showed where GLN can be given safely, via which route, at 
what time, and what dosages should be given to which patients.
Some of the same authors of the 2013 REDOXS study,17 revisited 
the recommendations for IV-GLN in 2014 and stated that 
‘supplementation of parenteral glutamine, predominantly as a 
component of parenteral nutrition (PN), may improve clinical 
outcomes when given to appropriate patients as part of complete 
nutrition support’.18 The authors also stated that ‘parenteral 
supplementation with glutamine should continue to be 
considered safe and may potentially improve outcomes in ICU 
Figure 1. The depletion of GLN during stress, and its consequences1,2,13.
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patients without specific contraindications’.18 In his 2015 
commentary, Wischmeyer15 reiterated that GLN still saved lives 
and that the right patients, including oncology patients, will 
continue to benefit from GLN-supplementation.
Supplementation on selected oncology 
settings
Administration route
Oral GLN is considered safe and effective in adults,19 but it is 
unclear whether oral GLN is as effective as IV-GLN, although 
animal and human studies show similar benefits by either 
route.20 Enteral GLN absorption occurs in the upper part of the 
jejunum, which leaves the rest of the gastrointestinal tract (GIT) 
unsupported. It is highly likely that parenteral GLN may become 
critical for the intestine when enteral nutrition (EN) is not 
feasible.6.The meta-analysis by Kang et al.21 found that GLN-
supplemented EN was superior in improving immune function, 
reducing the incidence of infectious complications, and 
shortening the hospital LOS, thereby playing an important role 
in the rehabilitation of surgical gastrointestinal cancer patients.
Oral GLN may reduce the duration and severity of 
mucositis,9,12,19,22,23 with fewer days on opiods.22,23 The exact 
mechanism by which oral GLN prevents mucositis is not clear.9 
Van Zyl’s systematic review20 on oral GLN provided new evidence 
of a significant reduction (p = 0.03) in > grade 2 mucositis with a 
relative risk reduction of 24%. Trends for less days of opiate use 
with mucositis22 were seen in autologous (p  < 0.01), but not 
allogeneic, bone marrow transplant (BMT) patients.19
Oral GLN may reduce graft-versus-host disease (GVHD).22,23 It 
may decrease the severity and duration of stomatitis in children 
and adults after chemotherapy, as well as in head and neck 
cancer patients.12
Oral GLN may also prevent or delay the occurrence of radiation-
induced oesophagitis among cancer patients treated by 
radiotherapy to the thoracic area with or without chemotherapy.11 
The reduction in oesophagitis also led to less weight loss in lung 
cancer patients undergoing thoracic irradiation.11 Optimal 
nitrogen retention was reached at a GLN dose of 0.57 g/kg/day in 
this group of patients.11 Oral GLN alone appeared to have no 
effect on mortality, 20,22 infections, time to neutrophil recovery, or 
relapses.22
Oral GLN may reduce some chemotherapy-induced 
complications, such as mucositis and diarrhoea, among colon 
and colorectal cancer patients,5 especially among those on 
5-fluorouracil/folinic acid chemotherapy.5,12 GLN 
supplementation maintains glutathione levels during the 
administration of doxorubicin, methotrexate, and 
cyclophosphamide.3 High-dose doxorubicin causes cardiac 
toxicity,3 but GLN up-regulates glutathione and induces heat 
shock proteins 72 and 27, which protect the myocardium.3 There 
are some studies that found a reduced severity of peripheral 
neuropathy in breast cancer patients on paclitaxel,24 when 
supplemented with 30  g oral GLN/day (10  g thrice daily).12 
However, there was no reduction in severity of paclitaxel-induced 
myalgias and arthralgias.12 In metastatic colorectal cancer 
patients on oxaliplatin, oral GLN significantly reduced the 
incidence and severity of peripheral neuropathy, without 
affecting survival or response to chemotherapy.25 GLN, when 
administered in conjunction with probiotics, reduces 
chemotherapy-induced diarrhea.24 GLN also significantly reduces 
the duration of diarrhoea, but has no effect on prevention.20
The review by Sayles et al. found weight gain or less weight loss in 
patients receiving oral GLN, but only one study showed a significant 
difference. In both Van Zyl’s review20 and the Cochrane review,26 
mean body weight changes were inconclusive and not significant.
Azman et al.27 states that their study is the first to show significant 
post-operative improvements in serum albumin (p < 0.001), fat 
free mass (p < 0.001), and patient QoL parameters (p < 0.05) after 
four weeks of enteral GLN supplementation at 0.3–0.4 g/kg/day. 
There was also a significant correlation (p  < 0.05) between 
retention of lean body mass and improved QoL with GLN 
supplementation.27
Studies conducted in paediatric oncology are limited. In children 
with solid tumours on chemotherapy, GLN supplementation 
showed significant improvements in pre-albumin, transferrin, 
lymphocyte counts, complement 3 and 4,19,28 antibiotic necessity,19 
as well as reduced stomatitis severity. Non-randomised preliminary 
clinical studies demonstrated safety. GLN supplementation may 
reduce hospital costs in children receiving chemotherapy or 
BMT.19 Currently, the reported reduction of severe mucositis or 
infection rates in children is not statistically significant.29 Sung et 
al.30 found that GLN was not consistently effective in reducing 
mucositis in paediatric patients in more than one study.
In the study by Ward et al.,31 GLN was safely given enterally or orally 
at 0.65 g/kg/day for five days alongside chemotherapy to patients 
aged > 1 to < 22 years old (mean = 8.8 years). GLN did not reduce 
the incidence or severity of oral mucositis, but significantly reduced 
both the number of patients requiring total parenteral nutrition 
(TPN) (p  = 0.049) and the amount of days necessary for TPN 
administration (p  = 0.023), thereby reflecting a possible 
improvement in ‘lower gut’ mucositis.31 Most other trials tested oral 
GLN at a daily dose of 4 g/m2 body surface area in various paediatric 
oncology patients receiving cancer treatment (Table 1).19
Table 1: Oral glutamine recommendations for the prevention of mucositis in children31,44
High risk patient groups Dose and duration Administration method
Intensive chemotherapy regimens, e.g.:
•  Burkitt’s Lymphoma
•  Acute Myeloid Leukemia
•  Give at 0.57 g/kg for duration of chemotherapy
•  Start administration after completion of leucovorin 
rescue as part of multi-agent regimens containing 
high dose methotrexate
•  Mix into any beverage or soft moist food
•  Dissolve 10 g powder in at 100 ml of clear liquid–
swish around in the mouth and swallow, or  
administer enterally
•  Use within 30 min
Radiotherapy to upper GIT, e.g.:
•  Head and neck cancers
•  Rhabdomyosarcoma
•  Give at 0.57 g/kg for duration of radiotherapy
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Opioid analgesics are usually needed in more severe cases of 
mucositis, because the condition is typically very painful. GIT 
mucositis presents with pain, nausea, vomiting, and diarrhea, 
and impairs dietary intake and QoL.33 Disruption of the GIT 
mucosal barrier can also cause translocation of microorganisms 
and/or endotoxins.35 Poor nutritional status may interfere with 
healing and mucosal regeneration by decreasing cellular 
migration and renewal.36
Mucositis severely affects QoL and clinical outcomes in cancer 
patients. Oral GLN, but not IV-GLN, may decrease mucositis and 
GVHD in BMT patients.23 A possible trend in the objective 
reduction of mucositis by glutamine supplementation in non-
BMT patients receiving chemotherapy and/or radiotherapy has 
been reported.37 Furthermore, a Japanese study38 using a 
combination of GLN, fibre and oligosaccharides (GFO) was the 
first retrospective comparative clinical study of mucosal injury in 
allogeneic HSCT using GFO. Iyama et al. concluded that GFO 
supplementation was an effective supportive therapy to 
decrease the severity of mucosal injury in HSCT.38
In the systematic review by Van Zyl,20 significant associations (RR 
0.14, p = 0.05) were reported in two studies with adult patients 
(n = 45) in which fewer grade 3 or 4 mucositis cases were present 
when patients received IV-GLN vs placebo. Significant results for 
interventions >14 days (RR 0.19, p = 0.0003) were also obtained 
in four studies (n  = 410) in which presence of grade 3 or 4 
mucositis was significantly less in the IV-GLN group after 14 days 
of consecutive administration.20 Thus, there was a trend towards 
reduced risk and a delay in the development of severe mucositis 
with IV-GLN. Nevertheless, too few studies exist to either support 
or refute that GLN supplementation either reduces the duration 
of mucositis or prevents its progression to severe mucositis.20
IV-GLN has been described as more effective than oral GLN in 
patients with haematological malignancies (both with and 
without BMT or HSCT), colorectal cancer, head and neck cancer, 
and solid tumours undergoing BMT or HSCT, as IV administration 
ensures full availability of the substrate.12,20 IV-GLN 
supplementation was favoured in many studies in order to 
bypass erratic bioavailability and variable compliance with oral 
administration, especially in patients with feeding difficulties.7
In the United States of America (USA), IV-GLN must be 
compounded from non-sterile powder, and Sayles et al.9 argue 
that oral GLN may be more appropriate for the prevention of 
mucositis under these circumstances.
IV-GLN protects the liver cells from oxidative injury by increasing 
intracellular glutathione during chemotherapy.3 The Academy of 
Since GLN becomes unstable in solution, enteral supplements 
are not routinely supplemented with GLN. Powdered GLN is 
recommended for enteral administration.20 A water-based 
solution of GLN should be prepared prior to GLN administration 
via a feeding tube to avoid clogging the tube, and should be 
used as soon as possible thereafter as the solution is not stable 
for long periods of time.8
The effectiveness of the IV dipeptide (L-alanyl-L-glutamine) in 
treating or preventing oral mucositis in head and neck cancer 
patients, as well as haematopoetic stem cell transplantation 
(HSCT) patients has not been established given the limited IV-
GLN research.32 Concerns also exist about the stimulation of 
tumour growth during GLN supplementation.12
The local effects of oral GLN differ from its systemic effects.9 
GLN’s gut protective effect is obtained by administering 
supplements either:
(1)  Intravenously (alone as a alanyl-glutamine dipeptide or 
with PN);22 or
(2)  Orally (alone as a reconstituted powder or as part of EN. 
It seems that oral GLN provides an enhanced gut protec-
tive effect,14,20 possibly due to the induction of heat shock 
protein number 72.14 However, IV-GLN has been shown 
to enhance the effect on chemotherapy more so than 
enteral GLN.12 Adequate GLN availability can benefit out-
comes for BMT patients by reducing the incidence of in-
fection and shortening the hospital LOS.12
Tumour growth
Tumour cells use GLN in protein catabolism for tumour growth, 
depleting GLN in the skeletal muscles of cancer patients, leading 
to cachexia (Figure 1). It is believed that tumours become GLN 
traps and worsen GLN loss in cancer patients, but also that GLN 
has the potential to retard or halt tumour growth due to its 
immuno-modulatory action.8 Various studies suggest that GLN 
supplementation suppresses tumour growth by restoring the 
function of natural ‘killer’ cells, improving protein metabolism,3 
and enhancing the effect of cancer therapy.9,11,20,22 The review by 
Kuhn et al.12 confirmed that GLN improves the clinical state of 
patients with a variety of malignancies without increasing 
tumour growth.
Mucositis
Mucositis is the mucosal damage occurring in the mouth, 
pharynx, larynx, oesophagus, and other areas of the GIT, due to 
damage caused by cancer therapies, including chemotherapy or 
radiation therapy (RT), or a combination of both.33 It is present in 
twenty to forty percent of patients receiving conventional 
chemotherapy, eighty percent receiving high-dose 
chemotherapy, and it occurs in almost all head and neck RT 
patients.33 Severe mucositis can lead to a temporary reduction in 
chemotherapy dose or delays in RT in 35% to 60% of patients, 
leading to a less favourable prognosis.9,33 The pathogenesis of 
mucositis is complex, and is thought to be initiated by cell 
damage from chemotherapy and/or RT. Factors that are believed 
to contribute to the amplification of tissue injury include: reactive 
oxygen species (i.e. free radicals), pro-inflammatory cytokines 
and pathways, and metabolic by-products of colonising 
microorganisms.33 There are a number of classification systems 
used for staging mucositis, including that of the World Health 
Organisation (WHO) shown in Table 2.
Table 2: WHO staging of mucositis34
WHO score Classification
Grade 1 Soreness, with or without erythema, 
but no ulceration
Grade 2 Erythema, ulcers, pain. Patient can 
swallow solid food
Grade 3 Ulcers with extensive erythema. 
Significant pain. Inability to swallow 
solid food. Liquid diet only
Grade 4 Ulcers. Intolerable pain. Feeding by 
mouth impossible, enteral or paren-
teral nutrition obligatory. Cannot talk
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effectiveness of L-alanyl-L-glutamine in treating or preventing 
oral mucositis has not been established given the limited 
research in head and neck and HSCT patients.32 The guidelines 
also recommend caution when considering provision of IV-GLN 
to oncology patients who have hepatic insufficiency or failure. 
Liver and kidney functions should be monitored.32
Both the 2009 ESPEN guidelines on PN in non-surgical oncology39 
and the 2009 ASPEN guidelines on nutrition support during 
adult anti-cancer treatment in HSCT40 state that HSCT patients 
may benefit from GLN-supplemented PN,16,22,32,40,41 at a dose of 
0.2 to 0.5  g/kg/day.32,41 and should be initiated early in the 
treatment course.32 The dosage recommendations for 
administration of intravenousl glutamine in adults are set out in 
Table 3.
The Multinational Association of Supportive Care in Cancer and 
International Society of Oral Oncology (MASCC/ISOO) has set out 
evidence-based clinical practice guidelines for mucositis.33 The 
guidelines, published by the European Society for Medical 
Oncology, as well as the USA National Comprehensive Cancer 
Network, are both adaptations of the MASCC/ISOO guidelines. 
The latest updated guidelines, based on systematic reviews of 
evidence for various interventions, were published in May 2014. 
However, owing to inadequate or conflicting evidence, a 
guideline was not possible in relation to GLN for all cancers, 
except in HSCT, where the recommendation was against the IV-
GLN for the prevention of mucositis, based on level 2 evidence 
from previously published criteria used by MASCC.33,43 IV-GLN is 
not recommended to prevent or treat oral mucositis in patients 
receiving high-dose chemotherapy prior to HSCT.43 The MASCC/
ISOO panel was unable to form a guideline on the systemic use 
of GLN specifically for the prevention of gastrointestinal 
mucositis (excluding the oral cavity), since newer evidence has 
emerged which is in conflict with their previous guideline; and, 
hence, advised against the use of systemic GLN in patients on 
chemotherapy.33
The 2011 ASPEN position paper on GLN-supplemented PN41 
state that specific patient populations may benefit from the use 
of PN GLN when indicated.41 However, they did state that the full 
benefit of PN GLN supplementation is still unclear since no effect 
was seen in post-autologous BMT patients, whereas reduced LOS 
was seen when data from allogeneic and autologous transplants 
was combined.32,41 They recommend that initiation of PN GLN 
supplementation in suitable candidates should probably occur 
soon after admission, and in doses of 0.2 to 0.5 g/kg/day, to be 
effective.41 The ASPEN 2011 guidelines state that due to limited 
available data, no recommendations regarding the use of GLN 
supplemented PN can be made in paediatric and neonatal 
patients.41
There is no evidence of any clinical toxicity or generation of toxic 
metabolites at doses up to 0.3 g/kg.11 There is little evidence for 
short periods of GLN administration (<7 days). A greater benefit 
was seen after at least 14 days, when GLN levels appeared most 
affected.20 The dosage recommendations for administration of 
oral glutamine in adults are set out in Table 4.
The 2016 ASPEN guidelines for critically ill patients47 suggest that 
neither supplemental enteral nor parenteral GLN should be 
routinely used in critically care, but do not specifically address 
the use of GLN in an oncology setting. Kuhn et al.12 made no 
oncology-specific recommendations on GLN supplementation’s 
route, dose, timing or duration. As stated previously, since 
Nutrition and Dietetics (AND)32 associates IV-GLN with improved 
nitrogen balance and decreased morbidity in HSCT patients. 
There was an increase in short-term survival in allogeneic-HSCT 
with GLN-containing PN (Alanyl-GLN; 0.3–0.4  g/kg/body 
weight).12 Both the ESPEN guidelines on PN in non-surgical 
oncology,39 and the 2009 ASPEN guidelines on nutrition support 
during adult anti-cancer treatment and haematopoietic cell 
transplantation,40 state that HSCT patients may benefit from 
GLN-supplemented PN.16,22,40,41 Both organisations gave this 
recommendation a mid-level grade of evidence.41 IV-GLN should 
be initiated early in patients undergoing HSCT.32,41,42
A decreased hospital LOS was found when data from allogeneic 
and autologous BMT patients were combined.32 A 
recommendation was made against the use of IV-GLN for the 
prevention of oral mucositis in patients receiving high-dose 
chemotherapy prior to HSCT.43 It seems that IV-GLN 
supplementation does not benefit well-nourished 
haematological and solid tumour patients treated by high-dose 
chemotherapy and autologous BMT.12
Murray and Pindoria44 recommend that PN with GLN can be 
considered in patients with severe gastrointestinal failure, which 
can possibly cause one to consider including haematology 
patients with typhlitis or ileus.
PN with GLN may also be associated with fewer infections,16,26 
but not with shorter hospital LOS.16,20,26 There is insufficient data 
on whether GLN supplementation reduces the incidence of 
infection, but Van Zyl’s systematic review did find a trend towards 
a reduction.20 A significantly lower incidence of infection and 
hyperglycaemia was seen in GIT-malignancy surgery patients on 
GLN-supplemented PN (0.5 g/kg body weight/day).15 There was a 
reduction in infections with IV-GLN in patients undergoing BMT. 
However, there was also an increase in relapse in autologous 
transplantation patients in two small studies.12,20,23
In paediatric HSCT patients, IV-GLN supplementation decreased 
drug-related toxicity,45 reduced the duration of fever, 19,45 and 
decreased the incidence of sinusoidal obstruction syndrome 
(OR = 0.195, p = 0.067).45 The evidence that IV-GLN reduces both 
the incidence and severity of mucositis was not statistically 
significant,29 although Kuskonmaz et al.45 did notice a trend (p = 
0.1118) towards a reduced incidence of severe mucositis (grade 
3 and 4). There is also no significant evidence that IV-GLN 
supplementation reduces infection rates,19,29 hospital LOS,19,29 
GVHD, mortality, or the need for total PN use in children.19
Guidelines
Suitable candidates for IV-GLN include, in particular, critically ill 
patients with burns, trauma, or cancer.15,46 Wischmeyer et al.18 
recommend that IV-GLN supplementation, as a component of 
nutrition support, be considered as an approach to improve 
outcomes of critical illness in selected patients. The ASPEN 2016 
guidelines on nutrition support for adult critically-ill patients also 
recommend against routine IV-GLN supplementation in the 
critical care setting; but, when PN is used, consideration should 
be given to supplementing the PN with GLN.47 It should be noted 
that cancer patients also do get admitted to ICU, especially 
surgical and haematological cancer patients; and, therefore, the 
critical care setting guidelines may sometimes be applicable to 
this patient group.
IV-GLN ‘may or may not’ be recommended to prevent or treat 
oral mucositis in oncology patients with solid tumours, since the 
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peripheral neuropathy in oncology patients receiving specific 
chemotherapies has been reported.32 Wernerman50 recommends 
that GLN supplementation be restricted to where a safety 
protocol is used or within clinical studies.
oncology patients may be admitted to ICU, the guidelines for ICU 
should not be ignored. GLN ‘may or may not’ be recommended 
to prevent or improve chemotherapy-induced peripheral 
neuropathy, as only limited success in preventing or improving 
Table 4: Dosage recommendations for oral glutamine administration in adults
Notes: RIO: radiation induced oesophagitis; chemo: chemotherapy; RT: radiotherapy; GIT: gastrointestinal.
Recommendation Application Type of cancer treatment Duration Patient population References
0.42 g/kg/day (30 g/day) - Unspecified up to 10 weeks Oncology patients 20x
30 g/day Mucositis Radio-chemotherapy Oesophageal cancer 12
30 g/day Oral mucositis Anthracycline-based chemo-
therapy
Breast cancer 9







Diarrhoea duration Chemotherapy or BMT with 
or without chemo and/or RT





Oral mucositis Chemotherapy or BMT with 
or without chemo and/or RT




10 g three times a day RIO RT with or without chemo-
therapy
one month before starting 
radiation until one month 
after completion of radiation
RT to thoracic area (e.g. 
breast, head and neck, lung, 
lymphoma)
11, 53
Up to 40 g/day - BMT and high-dose chemo-
therapy
Haematological cancers 22x
Table 3: Dosage recommendations for intravenous glutamine administration in adults
BMT: bone marrow transplant; chemo: chemotherapy; EN: enteral nutrition; GIT: gastrointestinal tract;HSCT: haematopoetic stem cell transplantation; ICU: intensive care 
unit; IV: intravenous; MOF: multiple organ failure; PN: parenteral nutrition; RT – radiotherapy.
* The alanyl-glutamine dipeptide contains 13,5 g L-glutamine per vial.
Recommendation Form Timing/Duration Patient population References
0.1–0.42 g/kg/day (7.5–30 g/day) Dipeptide* 8–21 days - during chemotherapy 
or BMT with or without chemo and/
or RT





> 0.2 g/kg/day Critical illness 42, 48
>0.2–0.5 g/kg/day GLN-supplemented PN Soon after admission Critical care 41
0.22–0.42 g/kg/day (16–30 g/day) Dipeptide* 14–21 days - during chemotherapy 





0.3–0.6 g/kg/day Dipeptide* ICU 41, 49
(GLN=0.2–0.4 g/kg/d)
0.35–0.5 g/kg/day Dipeptide* ICU 15
0.3–0.5 g/kg/day As part of total PN ICU 6
<0.5 g/kg/day As part of total PN and/or EN After resolution of shock/MOF ICU 18
0.57 g/kg/day L-glutamine, as part of dipeptide* Up to 30 days Oncology patients on treatment 20
0.025 g/kg/hour L-glutamine, as part of dipeptide* Critical illness 42
0.57 g/kg/day Combined with PN Critical illness 42
0.65 g/kg/day Dipeptide* As early as possible Burns, trauma, critical illness 42
(GLN=0.5 g/kg/d)
20–30 g/day Exogenous Critical illness 6
0.6 g/kg/day GLN-supplemented PN Non-surgical oncology/HSCT 39
1 g/kg/day (70 g/day) Dipeptide* Up to 10 days Oncology patients on treatment 20
Up to 40 g/day Enteral or IV BMT and high-dose chemo 22
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pain and discomfort.20 GLN supplementation may improve 
QoL,20 by decreasing the incidence and/or severity of: 
chemotherapy-associated mucositis; irinotecan-associated 
diarrhoea; paclitaxel-induced neuropathy; anthracycline-
induced cardiotoxicity; and hepatic veno-occlusive disease 
during high-dose chemotherapy and HSCT.
No published clinical guidelines or recommendations exist 
regarding the use of PN GLN supplementation in neonatal or 
paediatric patients.41 Insufficient evidence exists to either 
recommend regular use of GLN in adults,3 or to provide guidance 
on GLN supplementation for prevention or reduction of severe 
mucositis.
Larger, multicentre, randomised placebo-controlled studies are 
needed in both adult and paediatric oncology populations3,19,20 
Since oncology is a diverse field, studies would have to be 
specific to the cancer-type, as well as the side effects experienced 
with the cancer-specific treatment. More clarity is needed on: 
oncology-specific GLN supplementation of PN alone, or in 
combination with enteral/oral GLN; infection reduction; the use 
of free L-glutamine vs the dipeptide; the administration timing 
and dose; as well as the cost benefit analysis.
At this stage, the way forward would be to follow the existing 
guidelines as far as possible. If uncertainty exists as to whether a 
patient would benefit from GLN use, the duty of the health care 
professional is to first do no harm, and therefore GLN 
administration should then be avoided.
Disclosure statement – No potential conflict of interest was 
reported by the authors.
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